Jānis Gardovskis

Medicine & Life Sciences

1. Latvia 100%
2. Breast Neoplasms 61%
3. Neoplasms 41%
4. Mutation 39%
5. Colorectal Neoplasms 35%
6. Ovarian Neoplasms 26%
7. Parathyroid Neoplasms 26%
8. Thyroid Gland 23%
9. Population 23%
10. Cadherins 22%
11. Triple Negative Breast Neoplasms 19%
12. Aztreonam 18%
13. Adenoma 18%
14. Appendicitis 16%
15. Fine Needle Biopsy 15%
16. Familial Prostate cancer 15%
17. Papillary Thyroid Cancer 15%
18. Thyroid Nodule 15%
19. Confidence Intervals 15%
20. Carcinoma 14%
21. Vancomycin 14%
22. Epithelial-Mesenchymal Transition 14%
23. Primary Hyperparathyroidism 14%
24. Tigecycline 13%
25. Germ-Line Mutation 12%
26. Prostatic Neoplasms 12%
27. Acute Necrotizing Pancreatitis 12%
28. Survival 12%
29. BRCA1 Gene 11%
30. Thyroid Neoplasms 11%
31. Neoplasm Metastasis 11%
32. Axilla 11%
33. Survival Rate 11%
34. Therapeutics 11%
35. Skin 10%
36. Genes 10%
37. Hereditary Nonpolyposis Colorectal Neoplasms 10%
38. Needle Biopsy 10%
39. Penetrance 10%
40. Platinum 10%
41. Debridement 9%
42. Lymph Nodes 9%
43. Baltic States 9%
44. Drug Therapy 9%
45. Safety 9%
46. Infections 9%
47. Glioblastoma 9%
48. Hereditary Neoplastic Syndromes 9%
49. omadacycline 9%
50. University Hospitals 9%